Capecitabine as salvage treatment in relapsed nasopharyngeal carcinoma: a phase II study.

Abstract

Capecitabine is active in relapsed NPC patients, achieving 48% objective responses, with mild toxicity. It is an attractive therapy to be administered in an outpatient setting.